Today: 7 February 2026
Subscribe
Browse Category

Pharmaceutical Industry News 9 January 2026 - 18 January 2026

Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

New York, Jan 18, 2026, 07:03 (EST) — Market closed ImmunityBio’s IBRX shares ended Friday at $5.52, jumping roughly 40% following a series of company updates that attracted momentum traders. Trading volume surged past 182 million shares. This shift is key as ImmunityBio heads into a shortened week, aiming to convert early interest in its first cancer drug into consistent revenue. Investors also received fresh insight on the company’s timeline for expanding ANKTIVA into a wider first-line bladder cancer market. ImmunityBio reported preliminary net product revenue of roughly $113 million for 2025 in a Friday release, with fourth-quarter revenue hitting
18 January 2026
·····
Johnson & Johnson stock is sleepy today — earnings next week may decide the next move

Johnson & Johnson stock is sleepy today — earnings next week may decide the next move

NEW YORK, January 16, 2026, 12:29 ET — Regular session Johnson & Johnson shares dipped slightly on Friday, showing more resilience than many peers in the healthcare sector ahead of the company’s earnings report next week. The stock slipped around 0.1% to $219.38, fluctuating between $218.43 and $220.14 during the session. Timing is crucial. A heavyweight like J&J stands among the first earnings reports in a packed U.S. calendar, with investors using its results to navigate an increasingly complex policy and geopolitical landscape. “With all the noise swirling around geopolitics and policy, earnings really have to drive the news cycle,”
16 January 2026
·····
Johnson & Johnson stock price edges higher after hours as Tecvayli data and earnings loom

Johnson & Johnson stock price edges higher after hours as Tecvayli data and earnings loom

New York, Jan 15, 2026, 19:27 EST — After-hours Johnson & Johnson shares (JNJ.N) rose about 0.5% in after-hours trading on Thursday to $219.57, after swinging between $215.93 and $219.73 during the regular session. The healthcare conglomerate is set to report fourth-quarter results on Jan. 21, with Chief Executive Joaquin Duato and Chief Financial Officer Joseph Wolk scheduled to lead an 8:30 a.m. ET conference call. Guidance for 2026 is likely to do most of the work on the day. (JNJ.com) Late on Wednesday, the company said its Phase 3 MajesTEC-9 study of Tecvayli (teclistamab) showed a 71% reduction in
16 January 2026
·····
Merck stock slips as FDA fast-track delays grab attention ahead of Feb. 3 earnings

Merck stock slips as FDA fast-track delays grab attention ahead of Feb. 3 earnings

New York, Jan 15, 2026, 13:56 EST — Regular session Shares of Merck & Co slipped 0.2% to $110.75 on Thursday, fluctuating within a range of $108.48 to $111.06 during the day. The shift arrives as investors adjust their outlook on the U.S. Food and Drug Administration’s new fast-track review process. Initially marketed as a shortcut, the effort is already encountering signs of pushback. The Commissioner’s National Priority Voucher program aims to slash review times to just one or two months for a select group of medicines. Merck has already landed vouchers for its experimental cholesterol drug enlicitide and a
15 January 2026
·····
Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

New York, Jan 14, 2026, 12:55 (EST) — Regular session Shares of Edgewise Therapeutics Inc (EWTX.O) were up 10.6% at $27.59 by 12:55 p.m. EST on Wednesday after the drug developer laid out a 2026 schedule for clinical readouts and trial starts across its muscle-disease and cardiac pipeline. The move matters because Edgewise is still pre-commercial, and its valuation hangs on when — and how cleanly — the next sets of data arrive. In biotech, dates can trade almost like earnings. Edgewise used the J.P. Morgan Healthcare Conference this week to tighten up its roadmap, giving investors a clearer sequence
14 January 2026
·····
Erasca stock jumps 10% as Wall Street lifts targets to $11 on ERAS-0015 data

Erasca stock jumps 10% as Wall Street lifts targets to $11 on ERAS-0015 data

New York, Jan 14, 2026, 12:38 PM ET — Regular session Shares of Erasca Inc jumped roughly 10% Wednesday, pushing higher after a string of price-target upgrades fueled by early trial results. The clinical-stage cancer drugmaker’s stock hit $8.29, up 10.5%. The significance lies in Erasca having no approved products. In early-stage biotech, just a few signs of tumor shrinkage can quickly shift expectations—especially in a high-profile target like RAS, a mutation family that’s been notoriously tough to tackle. The rally has traders caught off guard. With the next solid data still months off, the stock’s already moving as if
14 January 2026
·····
Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

New York, Jan 13, 2026, 15:07 EST — Regular session. Pfizer shares dipped 0.6% to $25.12 by mid-afternoon Tuesday, continuing a volatile stretch for the drugmaker as investors digested its recent comments on obesity treatments. The stock fluctuated between $24.98 and $25.42 during the session. The selling comes as CEO Albert Bourla pushes to sharpen Pfizer’s post-COVID growth narrative and justify its spending on new drugs. At Monday’s J.P. Morgan Healthcare Conference, Bourla likened the potential consumer demand for obesity meds to the early surge in Viagra sales and admitted Pfizer underestimated how quickly the “cash-pay” market—patients paying out of
13 January 2026
····
Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

New York, Jan 12, 2026, 09:54 EST — Regular session Atara Biotherapeutics shares plunged about 56% to $6.03 in early trading after the U.S. Food and Drug Administration rejected its cell therapy tabelecleucel, marketed as EBVALLO in Europe, for a rare post-transplant cancer. The stock was volatile, swinging between $4.77 and $15.40 as investors reacted to the news, with volume exceeding 1.4 million shares. (Reuters) The company said the FDA’s complete response letter — the agency’s formal notice that an application cannot be approved as submitted — came after the Jan. 9 market close. It confirmed previous Good Manufacturing Practice
12 January 2026
·····
Liquidia stock jumps after $148.3 million YUTREPIA sales update — what LQDA investors watch next week

Liquidia stock jumps after $148.3 million YUTREPIA sales update — what LQDA investors watch next week

New York, Jan 11, 2026, 08:01 EST — Market closed. Shares of Liquidia Corporation jumped 12.9% to close at $35.86 on Friday, following a strong sales surge for its inhaled treprostinil therapy, YUTREPIA. The stock traded between $29.41 and $38.07 throughout the day. This shift carries weight as Liquidia remains in the early phase of its commercial rollout. Investors want clear signs that demand will ramp up quickly enough to support the company’s pipeline without needing to raise capital soon. Liquidia reported preliminary, unaudited 2025 net product sales of YUTREPIA at roughly $148.3 million, with around $90.1 million coming in
11 January 2026
·····
Thermo Fisher Scientific Inc stock: Weaverville phase-out plan hits tape ahead of JPM talk, Jan. 29 earnings

Thermo Fisher Scientific Inc stock: Weaverville phase-out plan hits tape ahead of JPM talk, Jan. 29 earnings

New York, Jan 10, 2026, 15:53 EST — The market has closed. Thermo Fisher Scientific is set to wind down its Weaverville-area facility in western North Carolina, according to a WARN notice filed with the state. The document reveals permanent layoffs starting as early as Dec. 31, 2026, with the eventual closure slated for late 2027. The company plans to cut 421 jobs at its 275 Aiken Road site, beginning the first wave of separations at the end of 2026 and continuing through the following year. (WLOS) WARN, or Worker Adjustment and Retraining Notification, is a U.S. requirement for employers
10 January 2026
·····
AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

New York, January 9, 2026, 20:18 (EST) — Market closed AbbVie Inc. shares dropped 1.8% on Friday, closing at $220.08. The decline followed the drugmaker’s decision to lower its 2025 earnings forecast and a denial of reports suggesting it was in talks to acquire cancer-drug developer Revolution Medicines. Since 2023, AbbVie has spent over $20 billion on acquisitions, aiming to offset the impact from Humira’s patent expiration. (Reuters) The updated forecast is crucial since AbbVie’s deals aim to replace lost growth, and this charge came late in the year when investors were already preparing for a rough transition from aging
10 January 2026
······
Eli Lilly stock drops 2% as Zepbound arthritis data and Ventyx deal sink in

Eli Lilly stock drops 2% as Zepbound arthritis data and Ventyx deal sink in

New York, Jan 9, 2026, 17:30 EST — After-hours Eli Lilly and Co shares fell nearly 2% on Friday, closing at $1,063.56, after swinging between about $1,063 and $1,104 in the session. The stock was little changed after hours. The pullback comes as the drugmaker’s stock cools off from a fresh 52-week high set on Thursday, with traders quick to lock in gains after a fast run. The broader market rose on the day, but Lilly logged a second straight decline and ended the session about 6% below that recent peak. (MarketWatch) The latest company catalyst landed late Thursday, when
9 January 2026
···
1 2 3 4 5 … 12

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop